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ABSTRACT
In 1930 Mauriac described a syndrome characterized 
by the presence of growth impairment, hepatomegaly, 
delayed puberty and cushingoid features in patients 
with poorly controlled type 1 diabetes mellitus (T1DM). 
At that time, Mauriac syndrome was a common occur-
rence. This state was maintained even in the fifties and 
sixties of the last century. The introduction of modern 
methods of insulin and glucose monitoring decisively 
reduced the frequency of occurrence of this syndrome. 
The incidence of Mauriac syndrome decreased dramati-
cally, although it is still being reported. Often in these 
cases the patients present only some symptoms of this 
syndrome. The introduction of diagnostic tests allowed 
to find the genetic basis of these disorders in some of 
the cases. (Clin Diabetol 2017; 6, 3: 101–104)
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Introduction
Mauriac syndrome is characterized by obesity, 
growth failure, hepatomegaly and delayed pubertal 
maturation in patients with insulin-dependent diabetes 
mellitus. It is associated with poor control of diabetes 
mellitus. Currently the disease is a rare complication, 
but it is necessary to pay attention to the possibility of 
the existence of its individual characteristics. This ap-
plies in particular other forms of diabetes than type 1. 
The Mauriac team was first described in 1930 [1]. 
This syndrome was described as a result of poor meta-
bolic control of type 1 diabetes characterized by growth 
disturbance, delayed puberty, and very significant 
hepatic enlargement. The occurrence of this syndrome 
was associated with chronic hyperglycaemia.
The discovery of insulin is considered to be one of 
the greatest achievements of 20th century medicine. 
Before the age of insulin, young people with diabetes 
had no chance of life. Introduction of insulin made it 
possible to survive, but the duration of life was usually 
short because it was not possible to monitor blood 
glucose levels. At that time Mauriac’s syndrome was a 
frequent occurrence until the fifties and sixties of the 
last century [2–5].
The situation started to change a little when self-
control was introduced, based on the detection of 
sugar and acetone in urine. Mauriac’s syndrome was 
described mainly in children. This was probably related 
to the fact that older patients, if they were poorly com-
pensated, did not survive. As the treatment options im-
proved, the incidence of this syndrome also decreased. 
Introducing blood glucose level control, which took 
place at the end of the 1970s, dramatically increased 
the ability to control the metabolic compensation. The 
possibility of at home glycaemia checking was a huge 
breakthrough in the treatment of diabetes, the second 
most significant right after the invention of insulin.
In subsequent years, due to the improvement of 
diabetes treatment, the occurrence of the Mauriac 
syndrome continued to decrease but the features of 
this syndrome such as growth disorders, overweight, 
or delayed maturation were relatively common [6–10].
Monitoring of blood glucose levels has made it pos-
sible to fundamentally change the criteria of diabetes 
control and to introduce intensive insulin therapy. This 
has played a huge role in the prevention of chronic 
complications of diabetes, including the reduction 
of the Mauriac syndrome. Further improvements in 
metabolic control were the result of better and better 
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insulin delivery, improved methods of administration, 
and improved blood glucose monitoring.
The frequency of the Mauriac syndrome has de-
creased drastically, however, it is still being described. 
Children with type 1 diabetes and poor metabolic 
control are at risk of developing Mauriac syndrome, 
similar complication may occur in type-1 or type-2 adult 
diabetics; namely, glycogenic hepatopathy [11, 12].
Portugese authors presented an analysis of 91 pa-
tients with type 1 diabetes mellitus in which 6 patients 
were diagnosed with Mauriac syndrome [13].
All had a previous history of poor glycemic control 
before the diagnosis of MS with glycated hemoglobin 
(HbA1c) between 8.8 and 12.9%. Increase of hepatic 
enzymes was present in all the patients; 4 of them 
had associated hepatomegaly. All the girls presented 
puberty delay and cushingoid features.
Schmetz et al. described two cases of Mauriac syn-
drome in which after metabolic control was achieved, 
reduction of hepatomegaly and the disappearance of 
cushingoid features were observed, proving the revers-
ibility of the syndrome [14].
An interesting study was presented by American 
authors who analyzed the cases of Mauriac’s syndrome 
observed for over 30 years [15].
These authors have noted that the use of adequate 
insulin therapy may cause withdrawal of the symptoms. 
However, the authors pointed out that insulin therapy 
cannot be too aggressive because it can lead to a dramatic 
deterioration of diabetic retinopathy and nephropathy.
One of the symptoms in Mauriac syndrome is 
hepatomegaly. In a randomized, double-blind, placebo-
controlled study in a group of 10 children with type 1 
diabetes the most frequent finding was glycogen 
degeneration of the plasma and nuclei of hepatocytes 
which agrees with the reports of other authors [16].
A relatively frequent lesion was observed in 4 cases 
of fatty degeneration of the liver regarded by most au-
thors as a lesion occurring mainly in adult-onset diabetes.
Fitzpatrick et al. presented a histological analysis of 
the liver in a group of thirty-one young people, median 
age of 15.1 years and the average duration of diabetes 
in this group was 10 years [17].
Hepatomegaly was present in 16% of the cases. 
Liver biopsy was undertaken in 19 (61%) ones. Signifi-
cant steatosis, inflammation and fibrosis were detected 
in all of the liver biopsies.
English authors, basing on their own observations 
and review of the literature, have expressed the view 
that regular abdominal examinations are recommended 
for all children and young people with long lasting, 
poorly controlled diabetes (HbA1c persistently > 9.5%) 
in the presence of Mauriac syndrome [18].
One of the complications of type 1 diabetes is 
growth disturbance, which is linked to classic micro-
vascular diabetic complications [19].
Discussion
Despite advances in medical care of children with 
T1DM, growth remains suboptimal in this population 
and likely reflects ongoing metabolic disturbances. 
The causes of growth disorders in juvenile type 1 
diabetic patients are complex. On the one hand, this 
is due to the fact that there are still many areas in the 
world where diabetes treatment is at a very low level. 
The cause of liver enlargement in this syndrome is 
glycogenic hepatopathy. It develops due to excessive 
accumulation of glycogen in the hepatocytes [20].
It is recommended to differentiate glycogenic 
hepatopathy from nonalcoholic fatty liver disease 
(NAFLD), which is the most common cause of chronic 
liver disease in type 2 diabetes, however it also occurs 
in type 1 diabetes [21]. The final determination of the 
nature of hepatomegaly requires liver biopsy [22, 23].
Brouwers et al. described a case study of glycogenic 
hepatopathy co-occurrence with increased hepatic gly-
cogen storage and increased plasma lactate levels [24]. 
Recently Canadian authors have linked the occurrence 
of glycogenic hepatopathy with lactic acidosis [25]. 
These authors claim that further research is required 
to explain the pathophysiology of lactic acidosis in 
glycogenic hepatopathy. 
In consideration of the pathogenesis of the Mau-
riac syndrome and accompanying growth disorders, 
reduced Insulin-like growth factor-1 (IGF-1), IGF binding 
protein-3 (IGFBP-3) levels and growth hormones levels 
or production of inactive forms of these hormones are 
taken into account [26, 27].
The development of genetic research has made it 
possible to determine the presence of genetic condi-
tions in some cases of the Mauriac syndrome. Such 
studies have recently been reported by MacDonald et 
al. [28]. The authors noted that the mutation in PHKG2 
(phosphorylase kinase catalytic subunit gamma 2), 
combined with hyperglycaemia, together with glycog-
enolysis, caused severe hepatomegaly. 
Mauriac syndrome was also described in a case of 
9-year-old girl who was diagnosed with neonatal diabe-
tes at 3 months of age due to mutation in KCNJ11 [29].
One of the symptoms of Mauriac syndrome, along 
with hepatomegaly and growth failure is delayed 
pubertal maturation. In the unadulterated diabetes, 
increased levels of advanced glycation end products 
suppress activation of the gonadotropin-releasing 
hormone (GnRH) pulse generator, resulting in pubertal 
delay [30].
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One of the characteristics of the Mauriac syndrome 
is obesity, however, recently some non-obese patients 
have been reported as well [31].
Mauriac syndrome illustrated by the prints of Polish 
authors attached with their consent (Fig. 1, 2).
Conclusions
In early years of insulin therapy, severe growth re-
tardation with pubertal delay, obesity and hepatomeg-
aly such as in Mauriac syndrome, have been reported 
often in patients with insulin-dependent diabetes 
mellitus (IDDM). These conditions are now rare due to 
improvements in insulin delivery and glycaemic control. 
However, one should pay attention to the possibility of 
occurrence of individual features of this syndrome. One 
should also remember that the Mauriac syndrome may 
occur in other types of diabetes. Syndrome has been 
described in monogenic forms of diabetes. 
It is crucial to be aware of Mauriac syndrome’s 
extreme importance since most clinical features are 
reversible with better glycaemic control.
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